AbCellera Biologics Inc vs Bio-Rad Laboratories, Inc. Class A Common Stock — how do they compare? AbCellera Biologics Inc trades at $9.47 (market cap $2.99B), while Bio-Rad Laboratories, Inc. Class A Common Stock trades at $352.64 (market cap $9.43B). The key difference: Bio-Rad Laboratories, Inc. Class A Common Stock is far larger — about 3.2× AbCellera Biologics Inc's market cap. Which is the better fit depends on your goals.
| ABCL | BIO | |
|---|---|---|
Market Cap | $2.99B | $9.43B |
Sector | Health | Health |
52-Week High | $9.76 | $356.25 |
52-Week Low | $2.78 | $241.71 |
Enterprise Value | $2.58B | $9.18B |
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) surged 34.78% to $9.34, driven by positive Phase 2 trial results for its menopause drug ABCL635. Despite negative net income margins and cash burn, analyst consensus is strongly bullish with a $15.50 price target. The stock shows a bullish technical trend, with support at $8 and resistance at $10, though RSI levels indicate overbought conditions.
The outlook hinges on ABCL635's clinical progress and future revenue potential, but high valuation ratios and persistent losses pose significant risks. Investor sentiment is optimistic due to recent drug trial success, yet the company must demonstrate a path to profitability to justify current market enthusiasm.
Bio-Rad Laboratories (BIO) trades at $351.10, down 0.97% on the day but maintaining strength near its 52-week high. The stock shows bullish technical momentum with strong moving average support and recently beat Q2 2026 earnings estimates with $2.62 EPS versus $1.75 expected. Fundamentals show improving profitability with 29.41% net margin in 2025, though revenue remains flat at $2.6 billion. Analyst consensus remains positive with 7 buy ratings and $350 price target.
BIO presents a mixed outlook with strong technical momentum and improving profitability offset by flat revenue growth and elevated valuation multiples. The stock's current price aligns with analyst consensus target, suggesting limited near-term upside. Key risks include academic research market softness and competitive pressures in life science instruments. Institutional ownership trends show continued confidence with recent position increases by major funds.
Trailing returns across standard periods
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →